JP6587241B2 - リジン特異的なデメチラーゼ−１の阻害剤 - Google Patents

リジン特異的なデメチラーゼ−１の阻害剤 Download PDF

Info

Publication number
JP6587241B2
JP6587241B2 JP2016575362A JP2016575362A JP6587241B2 JP 6587241 B2 JP6587241 B2 JP 6587241B2 JP 2016575362 A JP2016575362 A JP 2016575362A JP 2016575362 A JP2016575362 A JP 2016575362A JP 6587241 B2 JP6587241 B2 JP 6587241B2
Authority
JP
Japan
Prior art keywords
optionally substituted
pharmaceutically acceptable
acceptable salt
compound
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016575362A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519781A (ja
JP2017519781A5 (enExample
Inventor
チェン，ヤング，ケイ．
カノウニ，トウフィケ
スタッフォード，ジェフリー，アラン
ヴィール，ジェイムス，マービン
Original Assignee
セルジーン クオンティセル リサーチ，インク．
セルジーン クオンティセル リサーチ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54938856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6587241(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by セルジーン クオンティセル リサーチ，インク．, セルジーン クオンティセル リサーチ，インク． filed Critical セルジーン クオンティセル リサーチ，インク．
Publication of JP2017519781A publication Critical patent/JP2017519781A/ja
Publication of JP2017519781A5 publication Critical patent/JP2017519781A5/ja
Application granted granted Critical
Publication of JP6587241B2 publication Critical patent/JP6587241B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polyamides (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2016575362A 2014-06-27 2015-06-26 リジン特異的なデメチラーゼ−１の阻害剤 Expired - Fee Related JP6587241B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462018365P 2014-06-27 2014-06-27
US62/018,365 2014-06-27
PCT/US2015/038089 WO2015200843A1 (en) 2014-06-27 2015-06-26 Inhibitors of lysine specific demethylase-1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019087186A Division JP6851418B2 (ja) 2014-06-27 2019-05-03 リジン特異的なデメチラーゼ−１の阻害剤

Publications (3)

Publication Number Publication Date
JP2017519781A JP2017519781A (ja) 2017-07-20
JP2017519781A5 JP2017519781A5 (enExample) 2018-08-09
JP6587241B2 true JP6587241B2 (ja) 2019-10-09

Family

ID=54938856

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016575362A Expired - Fee Related JP6587241B2 (ja) 2014-06-27 2015-06-26 リジン特異的なデメチラーゼ−１の阻害剤
JP2019087186A Expired - Fee Related JP6851418B2 (ja) 2014-06-27 2019-05-03 リジン特異的なデメチラーゼ−１の阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019087186A Expired - Fee Related JP6851418B2 (ja) 2014-06-27 2019-05-03 リジン特異的なデメチラーゼ−１の阻害剤

Country Status (28)

Country Link
US (3) US10011583B2 (enExample)
EP (1) EP3160956B1 (enExample)
JP (2) JP6587241B2 (enExample)
KR (1) KR102438302B1 (enExample)
CN (1) CN106660987B (enExample)
AU (2) AU2015279591A1 (enExample)
BR (1) BR112016030697B1 (enExample)
CA (1) CA2953810C (enExample)
CL (1) CL2016003350A1 (enExample)
CO (1) CO2017000362A2 (enExample)
CY (1) CY1123475T1 (enExample)
DK (1) DK3160956T3 (enExample)
EA (1) EA030946B1 (enExample)
EC (1) ECSP17005635A (enExample)
ES (1) ES2812626T3 (enExample)
HR (1) HRP20201337T1 (enExample)
HU (1) HUE050564T2 (enExample)
IL (1) IL249733B (enExample)
LT (1) LT3160956T (enExample)
MX (1) MX376632B (enExample)
PL (1) PL3160956T3 (enExample)
PT (1) PT3160956T (enExample)
RS (1) RS60658B1 (enExample)
SG (2) SG10201911220TA (enExample)
SI (1) SI3160956T1 (enExample)
SM (1) SMT202000443T1 (enExample)
WO (1) WO2015200843A1 (enExample)
ZA (1) ZA201700069B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11028066B2 (en) 2014-06-27 2021-06-08 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2920257C (en) 2013-08-06 2023-02-21 Imago Biosciences Inc. Kdm1a inhibitors for the treatment of disease
PL3164380T3 (pl) * 2014-07-03 2022-04-04 Celgene Quanticel Research, Inc. Inhibitory lizyno-specyficznej demetylazy-1
BR112017017074A2 (pt) 2015-02-12 2018-04-10 Imago Biosciences Inc Compostos; sal; bis-tosilatos de n-((s)-5-((1r,2s)-2-(4- fluorofenil)ciclopropilamino)-1-(4-metilpiperazin-1- il)-1-oxopentan-2-il)-4-(1h-1,2,3-triazol-1-il)benzamida; sal de tosilato de um composto; sal de bis- tosilato de um composto; compostos, sais, polimorfos ou solvatos; composições farmacêuticas, método para inibição de kdm1a; métodos para tratamento de uma doença mediada por kdm1a ou globina; método para atingir um efeito em um paciente; método para inibir pelo menos uma função de kdm1a
KR20180011331A (ko) 2015-06-12 2018-01-31 오리존 지노믹스 에스.에이. Lsd1 억제제와 관련된 바이오마커 및 그의 용도
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
WO2017157825A1 (en) 2016-03-15 2017-09-21 F. Hoffmann-La Roche Ag Combinations of lsd1 inhibitors for use in the treatment of solid tumors
JP2019512546A (ja) 2016-03-16 2019-05-16 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｋｄｍ１ａ標的会合を決定するための方法、およびそれに有用な化学プローブ
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US11390590B2 (en) 2016-08-16 2022-07-19 Imago Biosciences, Inc. Methods and processes for the preparation of KDM1A inhibitors
US20190256930A1 (en) 2016-11-03 2019-08-22 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
WO2018190323A1 (ja) * 2017-04-10 2018-10-18 三井化学アグロ株式会社 ピリドン化合物と有害生物防除剤を含有する有害生物防除組成物および有害生物の防除方法
JP2020121925A (ja) * 2017-04-10 2020-08-13 三井化学アグロ株式会社 ピリドン化合物とキノリン系化合物を含有する有害生物防除組成物および有害生物の防除方法、ならびに新規キノリン系化合物
JP7089506B2 (ja) * 2017-04-10 2022-06-22 三井化学アグロ株式会社 ピリドン化合物を有効成分として含有する抗真菌剤およびその使用方法
CN110996949A (zh) 2017-08-03 2020-04-10 奥瑞泽恩基因组学股份有限公司 用于治疗行为改变的方法
CN112368272B (zh) * 2018-03-21 2023-04-21 苏州浦合医药科技有限公司 Shp2抑制剂及其用途
ES2977656T3 (es) * 2018-05-11 2024-08-28 Imago Biosciences Inc Inhibidores de KDM1A para el tratamiento de enfermedades
JP7536316B2 (ja) 2019-03-20 2024-08-20 オリソン ヘノミクス，ソシエダ アノニマ 境界性パーソナリティ障害の処置方法
US20220151999A1 (en) 2019-03-20 2022-05-19 Oryzon Genomics, S.A. Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
JP2022546908A (ja) 2019-07-05 2022-11-10 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法
WO2022214303A1 (en) 2021-04-08 2022-10-13 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for treating myeloid cancers
US20250032454A1 (en) * 2021-10-18 2025-01-30 Imago Biosciences, Inc. Kdm1a inhibitors for the treatment of disease
JP2025516647A (ja) 2022-05-09 2025-05-30 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｌｓｄ１阻害薬を用いる悪性末梢神経鞘腫（ｍｐｎｓｔ）の治療法
CN119497613A (zh) 2022-05-09 2025-02-21 奥莱松基因组股份有限公司 使用lsd1抑制剂治疗nf1-突变肿瘤的方法
JP2025538876A (ja) 2022-11-24 2025-12-02 オリゾン・ゲノミクス・ソシエダッド・アノニマ がん治療のためのｌｓｄ１阻害薬とメニン阻害薬の組合せ

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994325B2 (en) * 2005-03-14 2011-08-09 Merck Sharp & Dohme Corp. CGRP receptor antagonists
WO2007149448A2 (en) 2006-06-21 2007-12-27 E. I. Du Pont De Nemours And Company Pyrazinones as cellular proliferation inhibitors
UA98961C2 (uk) 2007-06-27 2012-07-10 Астразенека Аб Похідні піразинону та їх застосування у лікуванні легеневих захворювань
CL2008002793A1 (es) 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
WO2012013727A1 (en) * 2010-07-29 2012-02-02 Oryzon Genomics S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
BR112014031068A2 (pt) * 2012-06-12 2017-06-27 Abbvie Inc derivados piridinona e piridazinona
SMT202300014T1 (it) * 2013-12-11 2023-05-12 Celgene Quanticel Research Inc Inibitori della demetilasi lisina-specifica-1
CN103804312B (zh) * 2014-02-17 2016-04-20 四川百利药业有限责任公司 一类氮杂环化合物及其制备方法和用途
EA036672B8 (ru) * 2014-05-01 2021-01-13 Селджен Квонтисел Рисёрч, Инк. Ингибиторы лизин-специфической деметилазы-1
SI3160956T1 (sl) 2014-06-27 2020-11-30 Celgene Quanticel Research, Inc. Inhibitorji lizin-specifične demetilaze-1

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11028066B2 (en) 2014-06-27 2021-06-08 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1

Also Published As

Publication number Publication date
US20170137402A1 (en) 2017-05-18
MX2017000179A (es) 2017-05-01
HRP20201337T1 (hr) 2020-11-27
KR20170018913A (ko) 2017-02-20
PT3160956T (pt) 2020-09-01
ZA201700069B (en) 2018-04-25
US20180273505A1 (en) 2018-09-27
US10011583B2 (en) 2018-07-03
HUE050564T2 (hu) 2020-12-28
SI3160956T1 (sl) 2020-11-30
AU2015279591A1 (en) 2017-01-19
US20200172506A1 (en) 2020-06-04
US11028066B2 (en) 2021-06-08
EP3160956B1 (en) 2020-05-27
CY1123475T1 (el) 2022-03-24
CN106660987B (zh) 2020-11-06
BR112016030697A2 (pt) 2018-07-17
EP3160956A1 (en) 2017-05-03
AU2019261771B2 (en) 2020-09-24
IL249733B (en) 2020-07-30
WO2015200843A1 (en) 2015-12-30
JP2017519781A (ja) 2017-07-20
EP3160956A4 (en) 2018-01-10
EA030946B1 (ru) 2018-10-31
RS60658B1 (sr) 2020-09-30
ES2812626T3 (es) 2021-03-17
PL3160956T3 (pl) 2020-11-30
MX376632B (es) 2025-03-07
CL2016003350A1 (es) 2018-05-11
JP6851418B2 (ja) 2021-03-31
ECSP17005635A (es) 2017-03-31
CA2953810C (en) 2022-07-12
CA2953810A1 (en) 2015-12-30
BR112016030697B1 (pt) 2023-03-21
AU2019261771A1 (en) 2019-11-28
SG10201911220TA (en) 2020-02-27
US10597376B2 (en) 2020-03-24
SMT202000443T1 (it) 2020-09-10
IL249733A0 (en) 2017-02-28
JP2019167345A (ja) 2019-10-03
CO2017000362A2 (es) 2017-04-10
DK3160956T3 (da) 2020-08-31
CN106660987A (zh) 2017-05-10
EA201692513A1 (ru) 2017-05-31
KR102438302B1 (ko) 2022-08-30
LT3160956T (lt) 2020-09-10
SG11201610866PA (en) 2017-01-27

Similar Documents

Publication Publication Date Title
JP6587241B2 (ja) リジン特異的なデメチラーゼ−１の阻害剤
JP6768857B2 (ja) リジン特異的なデメチラーゼ−１の阻害剤
CN106659914B (zh) 赖氨酸特异性脱甲基酶-1的抑制剂
JP6525422B2 (ja) リジン特異的なデメチラーゼ−１の阻害剤
HK1231860B (en) Inhibitors of lysine specific demethylase-1
HK1231860A1 (en) Inhibitors of lysine specific demethylase-1
HK1235332A1 (en) Inhibitors of lysine specific demethylase-1
HK1235332B (en) Inhibitors of lysine specific demethylase-1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190206

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190503

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190805

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20190808

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190809

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190903

R150 Certificate of patent or registration of utility model

Ref document number: 6587241

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D13

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees